Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

ASH 2014: Highlights in multiple myeloma

Prof Philippe Moreau, Prof Keith Stewart, Prof Marivi Mateos, Prof Meletios Dimopoulos
ASH 2014: Highlights in multiple myeloma ( Prof Philippe Moreau, Prof Keith Stewart, Prof Marivi Mateos, Prof Meletios Dimopoulos )
8 Dec 2014

Tyrosine kinase inhibitor in combination with chemo shows benefit in acute myeloid leukaemia

Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany
Tyrosine kinase inhibitor in combination with chemo shows benefit in acute myeloid leukaemia ( Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany )
7 Dec 2014

Paediatric leukaemia treatment regimens lead to improved outcomes in adolescents and young adults

Dr Wendy Stock - University of Chicago, Chicago, USA
Paediatric leukaemia treatment regimens lead to improved outcomes in adolescents and young adults ( Dr Wendy Stock - University of Chicago, Chicago, USA )
7 Dec 2014

Targeted therapy effective in elderly patients with Philadelphia-positive acute lymphocytic leukaemia

Dr Oliver Ottmann - Goethe University, Frankfurt, Germany
Targeted therapy effective in elderly patients with Philadelphia-positive acute lymphocytic leukaemia ( Dr Oliver Ottmann - Goethe University, Frankfurt, Germany )
7 Dec 2014

First randomised evidence for benefit from adding a tyrosine kinase inhibitor in acute myeloid leukaemia

Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany
First randomised evidence for benefit from adding a tyrosine kinase inhibitor in acute myeloid leukaemia ( Dr Christoph Röllig - University Hospital Dresden, Dresden, Germany )
7 Dec 2014

Chemo-free treatment approach demonstrates positive responses in leukaemia patients

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA
Chemo-free treatment approach demonstrates positive responses in leukaemia patients ( Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA )
7 Dec 2014

Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma

Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA
Blocking PD-1 activity could be safe and effective in classical Hodgkin lymphoma ( Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA )
7 Dec 2014

Nivolumab shows early promise in Hodgkin lymphoma

Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA
Nivolumab shows early promise in Hodgkin lymphoma ( Dr Phillippe Armand - Dana-Farber Cancer Institute, Boston, USA )
7 Dec 2014

Blinatumomab demonstrates significant clinical activity in residual ALL

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany
Blinatumomab demonstrates significant clinical activity in residual ALL ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )
7 Dec 2014

New immunotherapy compound effective, safe in ALL patients with minimal residual disease

Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany
New immunotherapy compound effective, safe in ALL patients with minimal residual disease ( Dr Nicola Gökbuget - Goethe University Frankfurt, Frankfurt, Germany )
7 Dec 2014

T cell therapy leading to prolonged remission for children with aggressive leukaemia

Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA
T cell therapy leading to prolonged remission for children with aggressive leukaemia ( Dr Stephan Grupp - The Children's Hospital of Philadelphia, Philadelphia, USA )
7 Dec 2014

Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA
Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma ( Dr Craig Moskowitz - Memorial Sloan Kettering Cancer Center, New York, USA )
7 Dec 2014